The case describes the challenges of ImmunoVaccine (IMV), a small biotech company in Halifax, Canada faced founded. The company has seen early success in the effectiveness of its technology in the field of animal health and looking for ways to wider use of the potential of their technology, looking especially in human health. The company presented challenges in the context of the evolving relationship between the pharmaceutical and biotech industries. The case describes the different output … Read more »

The case describes the challenges of ImmunoVaccine (IMV), a small biotech company in Halifax, Canada faced founded. The company has seen early success in the effectiveness of its technology in the field of animal health and looking for ways to wider use of the potential of their technology, looking especially in human health. The company presented challenges in the context of the evolving relationship between the pharmaceutical and biotech industries. The case describes the various issues the company is about 2008, shortly after the new president and CEO has taken over. It then provides information on the strategy formulation and execution under the new CEO.
«Hide

from
Ella Korets-Smith,
Suhaib Riaz
Source: Ivey Publishing
18 pages.
Publication Date: Oct 13, 2010. Prod #: 910M72-PDF-ENG
ImmunoVaccine (IMV): Preparing for the “Valley of Death” HBR case solution Crossing

[related_post themes="flat"]